Literature DB >> 9380055

Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.

J Wissel1, F Masuhr, L Schelosky, G Ebersbach, W Poewe.   

Abstract

We treated 43 patients who had head tremor as the major complaint with local botulinum toxin type A (Btx A) injections into neck muscles: 29 patients were classified as suffering from tremulous cervical dystonia (TCD), and 14 had head tremor without dystonia (HT). All patients were clinically assessed by means of the Tsui scale and a 4-point pain scale at baseline and follow-up visit. Quantitative recordings of head tremor with a bidirectional accelerometer system (horizontal and vertical planes) placed on the forehead were obtained before and 2-3 weeks after Btx A injections. Muscle selection for an injection was based on the visible and palpable tremor oscillation in the involved neck muscles and on analysis of standardized simultaneous electromyographic recordings of six cervical muscles. Patients with HT received mean total doses of 400 units (U) of Dysport (Btx A) (range, 160-560 U) distributed between the two splenius capitis muscles. Patients with TCD received a mean total dose of 500 U Dysport (range, 320-720 U) injected into a mean of 3 muscles (range, 2-4 muscles). The condition of all patients with HT and of 26 of the 29 patients with TCD improved subjectively. The total on the Tsui scale as well as pain scores decreased significantly (p < 0.05) following treatment. Latency of onset, duration of improvement, and side effects showed no significant difference in HT and TCD. Amplitude of HT decreased significantly for both groups following treatment. The mean dominant peak frequency in TCD and HT was slightly less than 5 Hz and did not change significantly after treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9380055     DOI: 10.1002/mds.870120516

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Mechanism of Botulinum Toxin in the Relief of Chronic Pain.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  Essential Tremor.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

Review 3.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 4.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 5.  Botulinum toxin in multiple sclerosis.

Authors:  Wolfgang H Jost
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

6.  Contraction of abdominal wall muscles influences size and occurrence of incisional hernia.

Authors:  Samuel C Lien; Yaxi Hu; Adi Wollstein; Michael G Franz; Shaun P Patel; William M Kuzon; Melanie G Urbanchek
Journal:  Surgery       Date:  2015-03-25       Impact factor: 3.982

7.  Head accelerometry may be useful as a test of psychogenic head tremor.

Authors:  Vesper Fe Marie Llaneza Ramos; Mark Hallett
Journal:  Mov Disord Clin Pract       Date:  2014-12

Review 8.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  [Botulinum toxin treatment : therapy success in cases of depression and ongoing pension applications].

Authors:  A Bachhuber; G Reichel; M Doberenz; A Stenner; W Hermann
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

10.  A simplified ultrasonography-guided approach for neurotoxin injection into the obliquus capitis inferior muscle in spasmodic torticollis.

Authors:  Uwe Walter; Ales Dudesek; Urban M Fietzek
Journal:  J Neural Transm (Vienna)       Date:  2018-02-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.